Author

Kena A. Swanson

Pfizer (United States)ORCID 0000-0002-3389-8414Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander MuikiD· 3 shared Annaliesa S. AndersoniD· 3 shared Carla Iris Cadima Couto· 3 shared Kayvon ModjarradiD· 3 shared Kristin R. TompkinsiD· 3 shared Lyndsey T. MartineziD· 3 shared Uğur ŞahiniD· 3 shared Aaron Yam· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Alexander MuikORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Immunologynpj VaccinesPeer-reviewedJul 6, 2026

Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine

Chaitanya Kurhade, Wei J. Chen, Weiqiang Li…·Kayvon Modjarrad

This study evaluates the immunogenicity of an LP.8.1-adapted BNT162b2 vaccine against JN.1 sublineages, showing higher neutralizing antibody responses compared to other adapted vaccines.

1 citation

humanexperimental assay

𝕏 PostBluesky

ImmunologyNature CommunicationsPeer-reviewedDec 5, 2025

Immunologic and Biophysical Features of the BNT162b2 JN.1- and KP.2-Adapted COVID-19 Vaccines

Wei J. Chen, Kristin R. Tompkins, Ian W. Windsor…·Kayvon Modjarrad

Omicron JN.1- and KP.2-adapted BNT162b2 mRNA vaccines elicit stronger neutralizing antibody responses against circulating sublineages than previous vaccines, supporting annual strain updates.

14 citationstop 1%

mouseproteomics

𝕏 PostBluesky

Immunologynpj VaccinesPeer-reviewedNov 20, 2024

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

Kayvon Modjarrad, Ye Che, Wei Chen…·Kena A. Swanson

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

24 citationstop 2%

mouseexperimental assay

𝕏 PostBluesky